<DOC>
	<DOCNO>NCT01483170</DOCNO>
	<brief_summary>This trial study tolerability pharmacokinetic fexinidazole use two different dosage regimen repeat administration . The drug administer human healthy volunteer sub-saharan origin together food , day 10 day , load dose 4 day .</brief_summary>
	<brief_title>Multiple Dose Study Evaluate Security , Tolerance Pharmacokinetic Fexinidazole ( Drug Candidate Human African Trypanosomiasis ) Administered With Loading Dose With Food</brief_title>
	<detailed_description>Objectives : Primary Objectives : To assess safety tolerability two different fexinidazole dose regimen , 10 day repeat administration feed condition healthy male sub-Saharan volunteer . Secondary objective : To validate exposure fexinidazole , M1 M2 different dose regimen feed condition 10 day order evaluate appropriate administration regimen pivotal phase II/III study . Methodology/Study Design : Two dose regimen consist repeated oral ascend dose ( OAD ) dose feed condition two different ascend loading dos 4 day follow dose 6 day evaluate . The study conduct double-blind condition clinical bioanalytical part . For dose regimen , subject reside clinical unit even Day -2 afternoon Day 17 include 8 day safety follow ( 168 h post last dose ) .</detailed_description>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<criteria>Male healthy volunteer 18 45 year age , All subject subSaharan African origin parent subSaharan African origin , Male subject body mass index ( BMI ) calculate weight kg/ ( height ) 2 18 28 kg/m2 inclusive screening , Able communicate well Investigator research staff comply requirement entire study , Provision write informed consent participate show signature volunteer consent form , Light smoker ( less 10 cigarette per day ) subject nonsmoker . No smoking ( use smoke substitute e.g . nicotine patch ) permit screen throughout study , Normal arterial blood pressure ( BP ) pulse rate , abnormal , consider clinically significant principal Investigator . These measure rest 5 min , Registered French Social Security agreement French law biomedical experimentation . Who direct question physical examination evidence clinically significant acute chronic disease , include know suspected HIV , HBV HCV infection , With clinically significant abnormality follow review prestudy laboratory test ( ASAT , ALAT alkaline phosphatase ( ALP ) must within normal range ) , vital sign , full physical examination ECG , Who within exclusion period define National Register Healthy Volunteers French Ministry Health , Who forfeit freedom administrative legal award guardianship , Unwilling give inform consent , Who positive laboratory test Hepatitis B surface antigen ( HbsAg ) , antiHIV 1/2 antiHCV antibody Who history allergy , intolerance photosensitivity drug , Who history serious allergy , asthma , allergic skin rash sensitivity drug , Who know suspected alcohol drug abuser ( 14 unit alcohol per week , one unit = 8 g 10 mL pure alcohol ) , Who drink 8 cup daily beverage contain caffeine , Who positive laboratory test urine drug screening ( opiate , cocaine , amphetamine , cannabis , benzodiazepine ) , Who undergo surgery donate blood within 12 week prior start study , Who take prescribed counter drug ( include antacid drug ) , exception paracetamol ( 3 g per day ) within 2 week prior first dose administration , Who clinical condition prior therapy , opinion Investigator , make subject unsuitable study , Who participate clinical trial investigational drug past 3 month precede study entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>